Navigation Links
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
Date:11/15/2007

p>

of these four trials evaluated a low dose (1/10th of the vaccine dose)

vaccination program. Preliminary results from this blinded trial

demonstrated excellent vaccine safety and positive anti-HIV-1 immune

responses to the vaccine in 9 of 11 participants where 9 people

received GeoVax HIV/AIDS vaccines and 2 received placebos. All trial

participants were normal, healthy individuals. Final results will be

compiled for later public release. The 2nd of four trials, initiated

September 2006, is designed to evaluate results from full dose

administration of GeoVax HIV/AIDS vaccines. Recent data indicates

excellent safety in this full dose trial with immune response data from

the majority of vaccine recipients.

-- In June and July, GeoVax announced it engaged Althea Technologies,

Inc., and BioReliance Corporation, as contract manufacturers for its

HIV-1 DNA and HIV-1 MVA (AIDS) vaccines. These vaccines will be

utilized in GeoVax's advanced Phase 2 clinical trials planned for early

2008. GeoVax HIV/AIDS vaccines are designed to prevent development of

Acquired Immunodeficiency Disease (AIDS) caused by the virus known as

HIV-1 by vaccinating individuals prior to AIDS virus infection. The

vaccine regimen employs a two-vaccine "prime-boost strategy." Trial

participants will be administered GeoVax HIV-1 DNA vaccine which

"primes" the immune system followed by GeoVax's HIV-1 MVA (Modified

Vaccinia Virus) boost. Both vaccines deliver over 50% of the AIDS virus

components but cannot cause AIDS. Safety and immunological results

from earlier as well as ongoing human trials are very encouraging thus

supporting planned acceleration of large scale Phase 2 clinical

studies.

-- In September, GeoVax announced receipt of an estimated $15,000,000

In
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. Biopure Announces 2007 Third Quarter Financial Results
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
7. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
8. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
9. Pharmacopeia Announces Third Quarter 2007 Financial Results
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... The global mHealth market ... 49,119.2 million by 2020, according to a new study ... to remain the dominant and fastest growing market segment, ... and an estimated CAGR of 49.7% from 2014 to ... Browse full research report with TOC on ...
(Date:7/1/2015)... , July 1, 2015 ... its Executive Board. Mr. Gert Weber has ... Invest AG as Chief Executive Officer (CEO) ... July 1 st , 2015. Mr. Weber brings more ... technological industries and has filled various executive management positions, ...
(Date:6/30/2015)... 2015 Ansell, a global leader ... of the first Ansell Cares ® H.E.R.O. ... The 2015 award, organised in partnership with the European ... display exceptional skill and quality in patient care, and ... Award ceremonies are taking place today in the winners, ...
Breaking Medicine Technology:mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2Ansell Announces European O.R. Nurse Hero Award Winners 2Ansell Announces European O.R. Nurse Hero Award Winners 3
... TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced ... luliconazole, one of the most potent and broad spectrum ... foot). The study was designed to assess the ... 14 days compared with once daily for 28 days. ...
... and KENILWORTH, N.J., Oct. 6 Centocor Ortho Biotech ... today that the European Commission has approved SIMPONI(TM) (golimumab) ... moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic ... , In the European Union, SIMPONI is approved ...
Cached Medicine Technology:TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal 2TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 2SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 5SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 6SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 8SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 9SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 10
(Date:7/1/2015)... ... July 01, 2015 , ... Did you know that infertility in men is ... we at Advanced Fertility Center of Texas (AFCT) would like to talk about some ... is often considered to be a “woman’s issue,” male fertility factors can play a ...
(Date:7/1/2015)... TX (PRWEB) , ... July 01, 2015 , ... As ... another symptom found in a significant number of women: leg pain. Northeast Houston Vein ... , Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Trevor L. Williams, ... South Florida and continued at USF earning a Master’s degree in Microbiology. He graduated ... member of the American Dental Association, the Florida Dental Association and the Academy of ...
(Date:7/1/2015)... ... 01, 2015 , ... Element Blue ™, a leading ... it has received trademark protection for its SensorInsight® computer software platform. SensorInsight® is ... multiple sources providing an environment where users can view and compare real-time and ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority Setting ... a top ten list they hope will guide future mesothelioma research. Surviving Mesothelioma ... it now. , More than 450 mesothelioma patients, caregivers, and healthcare ...
Breaking Medicine News(10 mins):Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2
... ... ... , , ... HARRISBURG, Pa. , ...
... ... ... ... ...
... alliance the Multilateral Initiative on Malaria (MIM), which advocates ... research environments in Africa. Malaria research has historically been ... has led to a huge gap in knowledge in ... in those areas where people are most affected by ...
... ... for the Apple iPhone and iTouch. The innovative torque application is the first of its ... San Diego, CA (PRWEB) February ... for the Apple iPhone and iTouch. The innovative torque application is the first of its ...
... ... has designated Houston Northwest Medical Center as a Blue Distinction Center for Spine Surgery. ... Houston, TX (Vocus) February 22, ... as a Blue Distinction Center for Spine Surgery. Blue Distinction Centers for Spine Surgery are ...
... ... ... ... ...
Cached Medicine News:Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 2Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 3Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 2Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 3Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 4Health News:Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful 5Health News:Malaria research must be based in Africa 2Health News:Flexible Assembly Systems Announces New Torque Calculator App for the iPhone 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 3Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 2Health News:AppDynamics Announces General Availability of AppDynamics v2.0 3Health News:AppDynamics Announces General Availability of AppDynamics v2.0 4Health News:AppDynamics Announces General Availability of AppDynamics v2.0 5Health News:AppDynamics Announces General Availability of AppDynamics v2.0 6Health News:AppDynamics Announces General Availability of AppDynamics v2.0 7Health News:AppDynamics Announces General Availability of AppDynamics v2.0 8Health News:AppDynamics Announces General Availability of AppDynamics v2.0 9
M2 cemented hip stem....
Cemented foundation 450 series....
A cementless femoral stem that promotes bone in-growth and reduces thigh pain....
The link ribbed hip stem for cementless primary hip replacement surgery....
Medicine Products: